banner
 
bar

program

slides
bar
 
 

Optimizing Outcomes in
Acute Coronary Syndrome

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period October 11, 2012 through October, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 1 hour and 16 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

1.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in acute coronary syndrome in the setting of diabetes.

Release Date

October 11, 2012

Expiration Date

October 11, 2014

Intended Audience

This program is intended for all cardiologists, endocrinologists, diabetes specialists, and other healthcare professionals who treat patients with diabetes and/or acute coronary syndrome.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logo This CME activity is supported by an
educational grant from Roche.

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

Distinguished Program Co-Chair
ROBIN CHOUDHURY, MD

Wellcome Trust Senior Research Fellow, Clinical Science
University of Oxford
Consultant Cardiologist, John Radcliffe Hospital
Clinical Director, Oxford Acute Vascular Imaging Centre
Oxford, England

Distinguished Program Co-Chair
R. SCOTT WRIGHT, MD

Distinguished Program Chairman
Consultant, Cardiovascular Diseases
Professor of Medicine
College of Medicine The Mayo Clinic
Rochester, Minnesota

D. JOHN BETTERIDGE, MD
Distinguished Faculty Presenter
Consultant Physician
University College London Hospitals
London, UK
Emeritus Professor of Endocrinology and Metabolism
University College London
Associate Dean, Royal Society of Medicine

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Understand the scientific and clinical research dimensions of ongoing investigations that are assessing antithrombotic, lipid-based, and novel, emerging strategies aimed at improving short- and long-term outcomes in ACS patients who also have T2D.
  • Discuss the rationale and potential clinical impact of therapeutic strategies based on new mechanisms of action, involving lipid management, glycemic control, and dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR) modulation.
  • Implement vasculopathy-mitigating therapies in diabetic patients that work through modification of comprehensive, cardiometabolic risk factor-based management and modulation.
  • Implement strategies in the intra-hospital and post-hospital phase of acute coronary syndrome (ACS) that address atheroinflammatory processes—plaque development, instability, and rupture—and that make an impact on the vaculopathic cascade leading to ACS in the setting of diabetes.
  • Apply evidence-based and guideline-supported strategies that are effective for residual CV risk reduction and secondary prevention of adverse thromboembolic events in the setting of diabetes after acute coronary syndrome (ACS).

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACCORD
ACS
Acute Coronary Syndrome
Adipocytes
Adiponectin
ALECARDIO
Aleglitazar
Aleglitazar
AMI
atherogenesis
Atherogenicity
Atherosclerotic Heart Disease
Atherothrombosis
BARI 2D Trial
Cardiometabolic
CHD
Clopidogrel
coronary heart disease

DCCT
Diabetes
Dual PPAR Agonists
dyslipidemia
Euro-Heart Survey
fenofibrate
Fibrate
FIELD
FPG
gemfibrozil
GIK
GLP-1
Glycemic Control
HbA1c
HDL,
HDL-C
Helsinki Heart Study
Hyperglycemia
Hyperglycemic

Insulin
ISAR-DIABETES
LDL
LDL-C
Lipid
MACE
Macrovascular
Muraglitazar
PERISCOPE
Peroxisome Proliferator-activator Receptors
Pioglitazone
PPAR
AMI
PPARa
PPARg
PPARd
PPAR-g agonism
Prasugrel

PROactive
Retinopathy Progression
Rosiglitazone
STENO-2
SYNCHRONY
HbA1c
SYNTAX
T2D
Glucose
T2DM
Tesaglitazar
Thiazolidinediones
triglyceride
Triglyceride/HDL-C
TRITON–TIMI 38
Type 2 Diabetes
TZD
Vascular Wall Disease